G
GT Biopharma, Inc. (GTBP)
NCM – Real vaqt narxi. Valyuta: USD
0.32
-0.02 (-5.92%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.33
+0.01 (2.29%)
Bozordan keyin: May 12, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.32
-0.02 (-5.92%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.33
+0.01 (2.29%)
Bozordan keyin: May 12, 2026, 7:59 PM EDT
GT Biopharma, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, o'zining Tri-specific Killer Engager (TriKE) va Tetra-specific Killer Engager (Dual Targeting TriKE) platformalariga asoslangan immunoonkologiya mahsulotlarini ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. U myeloid leykemiyalar yuzasidagi CD33 va agonistik tuyoqli oqsilni nishonga olgan 1-bosqich sinovlarida bo'lgan GTB-3650ni; rivojlangan qattiq o'smalar yuzasidagi B7-H3ni nishonga olgan 1-bosqich dozani ko'paytirish savat sinovida bo'lgan GTB-5550ni; va lyupus va boshqa otoimmün kasalliklarni davolash uchun ishlab chiqilayotgan klinik oldi bosqichdagi mahsulot nomzodi GTB-7550ni ishlab chiqadi. Kompaniya ilgari OXIS International, Inc. nomi bilan tanilgan va 2017 yil iyul oyida GT Biopharma, Inc. nomini o'zgartirgan. GT Biopharma, Inc. 1965 yilda tashkil etilgan va San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Alan Louis Urban CPA | CFO & Secretary |
| Mr. Michael Martin Breen L.L.B. | President, CEO & Executive Chairman |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | S-1 | forms-1.htm |
| 2026-04-07 | 8-K | form8-k.htm |
| 2026-03-06 | 10-Q/A | form10-qa.htm |
| 2026-03-02 | 8-K | form8-k.htm |
| 2026-03-02 | 10-K | form10-k.htm |
| 2026-01-28 | CORRESP | filename1.htm |
| 2026-01-21 | S-1 | forms-1.htm |
| 2025-12-02 | CORRESP | filename1.htm |
| 2025-11-26 | 8-K | form8-k.htm |
| 2025-11-14 | 10-Q | form10-q.htm |